VIP (Vasoactive Intestinal Peptide) Research Guide

VIP, or vasoactive intestinal peptide, is a small neuropeptide with wide effects in the body. It acts in the nervous system, the immune system, and the gut. The research record shows it as a signaling molecule with anti-inflammatory, neuromodulatory, and gut-related actions. It has also been studied in animal models of appetite, body composition, arthritis, and neural circuit function.

• VIP is a neuropeptide that functions as a neuromodulator and neurotransmitter.
• It has documented anti-inflammatory and immunoregulatory effects in cell and animal studies.
• Mouse studies link VIP signaling to feeding behavior and body composition.
• VIP also appears in brain circuits tied to learning, excitation, and inhibition.

What VIP is

Vasoactive intestinal peptide is a peptide found in the body’s nervous and peripheral systems. One review describes it as a major immunoregulatory neuropeptide that is widely distributed in the central and peripheral nervous system. The same review notes that immune cells can also synthesize VIP and express VIP receptors, which helps explain why its effects are not limited to neurons.

Another source describes VIP as a neuropeptide that functions as both a neuromodulator and neurotransmitter. In the gut, it is known for effects on smooth muscle relaxation and secretion. In the brain, it has been linked to circuit behavior and learning. In immune tissues, it has been studied as a regulator of inflammation and immune balance.

VIP is often discussed with other neuropeptides that shape signaling across tissues. In that group, PACAP is a useful comparison point because both peptides are studied for neurobiological and immune roles. That said, each peptide has its own receptor biology and research profile.

Immune and anti-inflammatory effects

The strongest research theme around VIP is immune regulation. A major review states that VIP is involved in the establishment and maintenance of immune deviation in immune privileged organs such as the central nervous system, and in the control of acute inflammation in peripheral immune organs. It also says VIP is involved in inflammatory and autoimmune disorders and has therapeutic interest.

In collagen-induced arthritis, one Johns Hopkins summary of a Nature Medicine study reported that VIP treatment in mice delayed disease onset, lowered incidence, and decreased severity. The same summary describes reduced inflammatory infiltrate, pannus formation, cartilage destruction, and bone erosion. It also lists several immune changes seen with VIP treatment, including inhibition of T-cell clonal expansion, lower Th1 cytokine production such as interferon-gamma, higher Th2 cytokine production such as IL-4, suppression of collagen-specific IgG antibodies, and increased anti-inflammatory signals such as IL-10 and IL-1 receptor antagonist.

That same arthritis report also noted suppression of inflammatory cytokines such as tumor necrosis factor and interleukin-1, plus reduced MMP-2 gelatinase expression and activity. Taken together, those findings support the idea that VIP can influence both autoimmune and inflammatory pathways in animal models.

A broader immune review describes VIP as a peptide with direct effects on immune cells and a role in tolerogenic dendritic cells, T-cell differentiation, and innate immune control. The review also points to endogenous and exogenous VIP as part of the immune response network. The key point is not that VIP is a simple anti-inflammatory switch, but that it can shape immune tone through several connected mechanisms.

What this means in research terms

The immune data are mostly preclinical. The studies point to biologic activity, not established clinical use. Still, the pattern is consistent: VIP can reduce inflammatory signals in models where immune activation is central. That makes it relevant to autoimmune and inflammatory research programs, especially when the goal is to understand signaling that pushes the immune system toward a less aggressive state.

Brain and nerve system roles

VIP also has a strong neuroscience profile. It is present in the brain and has been linked to neural circuit behavior, learning, and inhibitory control. A 2019 Neuron paper cited in the research bundle reported that vasoactive intestinal polypeptide-expressing interneurons in the hippocampus support goal-oriented spatial learning. That places VIP-related signaling inside a clear circuit-level function, not just a broad neurotransmitter category.

A 2026 Neuron study on all-optical electrophysiology revealed behavior-dependent dynamics of excitation and inhibition in the hippocampus. While that paper is not a VIP-only study, it fits the larger context of interneuron-mediated control in hippocampal networks, where VIP-expressing interneurons are part of the broader inhibitory landscape.

Another source in the bundle notes that VIP is abundant in neural cell lines and normal nervous tissue. Older literature also describes VIP as a transmitter candidate, which reflects its long history in neurobiology. The research record supports a view of VIP as a local signal that helps tune neural activity rather than drive a single on-off effect.

There is also research linking VIP to mood-related biology through inflammation. A Nature Scientific Reports paper in the bundle cites VIP plasma levels in a depression context, and it sits alongside literature on inflammation in depression. That does not prove a direct treatment role, but it shows why VIP is of interest in brain-immune cross-talk.

Appetite, weight, and body composition

VIP has also been studied in metabolism-related models. In one mouse study, VIP-deficient mice were compared with wild-type littermates. The design included group housing, free access to water and standard rodent diet, and repeated body composition measurements by nuclear magnetic resonance from 5 weeks of age to 22 weeks of age. The same work used the BioDAQ system to record feeding behavior under single-housing conditions after a 7-day habituation period.

The core value of this study is that it treated VIP as a biologic factor in feeding and body composition, not just a gut peptide. By using VIP neuropeptide-deficient mice, the research explored how removing VIP changes weight, fat mass, lean mass, and intake patterns across time. That kind of study is important because it connects peptide signaling to behavior and body composition in a measurable way.

Another source in the bundle describes VIP as involved in appetite, body composition, and energy balance. The exact downstream mechanisms are not settled here, but the experimental setup shows that VIP is a legitimate target for studying feeding behavior and metabolic regulation in animals.

For peptide researchers, this matters because appetite and inflammation often overlap. VIP sits at that intersection. It may be useful for studying how neuropeptide signaling affects feeding, fat storage, and systemic immune tone at the same time.

Gut, smooth muscle, and vasoactive effects

VIP has a classic role in the digestive tract. It is associated with smooth muscle relaxation, water and electrolyte secretion, inhibition of gastric acid secretion, and effects on intestinal function. One source in the bundle describes it as a peptide hormone that is vasoactive in the intestine and notes actions such as relaxation of enteric smooth muscle, dilation of peripheral blood vessels, stimulation of pancreatic bicarbonate secretion, and inhibition of gastrin-stimulated gastric acid secretion.

That same source also states that VIP stimulates secretion of water and electrolytes and helps increase motility. In simpler terms, VIP helps coordinate gut signaling, secretion, and movement. This is one reason it has been studied across gastroenterology and autonomic biology.

The blood-pressure and vessel-related effects are also part of the VIP story. The peptide’s name reflects its vasoactive behavior, and the research summary notes peripheral blood vessel dilation and coronary vasodilation. It also reports positive inotropic and chronotropic effects in the heart. These are classic physiologic effects that place VIP at the junction of neural signaling and cardiovascular control.

Cell and tissue signaling

VIP is not limited to one organ system. A cancer research paper from the bundle reports that VIP stimulated in vitro growth in a cell-based setting. Even without going beyond that paper’s title, the result is useful because it shows that VIP can influence cell behavior directly in culture.

That matters for research interpretation. If a peptide changes growth in vitro, then its signaling effects may reach beyond circulation or whole-body physiology. It may affect local tissue environments, receptor signaling, and cell state. Researchers should be careful, though, because in vitro growth effects do not automatically predict in vivo behavior.

Another point from the immune review is that VIP and its receptors appear in immune cells themselves. That opens the door to autocrine and paracrine signaling, where cells both produce and respond to the same peptide. This is one reason VIP is often framed as a local communication molecule rather than just a distant hormone.

What researchers should keep in mind

VIP has a broad evidence base, but much of it is still preclinical. The bundle contains animal studies, cell studies, and review articles. It does not provide a clinical dosing framework, and it does not support claims about routine human use. The most defensible reading is that VIP is an important signaling peptide with real biologic effects in immune, neural, gut, and metabolic systems.

Researchers should also avoid treating VIP as a single-purpose molecule. The same peptide can be involved in inflammation control, neural circuit modulation, secretion, and body composition. That range is useful, but it also means results may depend heavily on tissue type, receptor context, dose, timing, and model system.

One practical takeaway from the literature is that VIP is best studied in context. In the immune system, it may push toward tolerance or reduced inflammation. In the brain, it may shape inhibitory signaling and learning. In the gut, it acts on secretion and smooth muscle. In metabolism, it may influence feeding behavior and composition. The peptide’s value is in that cross-system reach.

FAQ

What is VIP?

VIP stands for vasoactive intestinal peptide. It is a neuropeptide that acts as a neuromodulator and neurotransmitter, and it has roles in the nervous system, immune system, and gut.

Is VIP only a gut peptide?

No. The gut is one important site, but the research also places VIP in the brain, immune tissues, and cardiovascular signaling. It is widely distributed across central and peripheral systems.

What does VIP do in immune research?

VIP has been linked to immune regulation, anti-inflammatory signaling, tolerogenic dendritic cells, and T-cell differentiation. In animal arthritis models, it reduced severity and shifted inflammatory markers.

What does VIP do in the brain?

VIP-expressing interneurons in the hippocampus have been tied to goal-oriented spatial learning. Other research places VIP in neural circuits that shape excitation, inhibition, and broader brain signaling.

Has VIP been studied for appetite or body composition?

Yes. Mouse studies using VIP-deficient animals tracked feeding behavior, body weight, and body composition over time. Those studies show that VIP is relevant to metabolic research, not just immune or neural biology.